Mon. 8 Apr 2024, 7:02am ET
Benzinga
News
The company announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine). In conjunction with the strategic process and focus on its late stage MicroPine asset, Eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses while continuing to support meaningful value generation from the company's two FDA-approved products.